Suomi - suomi - Fimea (Suomen lääkevirasto)

sintetica gmbh - phenylephrini hydrochloridum - injektioneste, liuos - 8.2 mg/ml - fenyyliefriini

Suomi - suomi - Fimea (Suomen lääkevirasto)

diagnostic green ltd. - indocyanine green - injektiokuiva-aine, liuosta varten - 5 mg/ml - indosyaniinivihreä

Euroopan unioni - suomi - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - kystinen fibroosi - muut hengitysteiden tuotteet - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Suomi - suomi - Fimea (Suomen lääkevirasto)

les laboratoires servier - indapamide, perindopril arginine - tabletti, kalvopäällysteinen - 2.5 mg / 0.625 mg - perindopriili ja diureetit

Suomi - suomi - Fimea (Suomen lääkevirasto)

les laboratoires servier - indapamide, perindopril arginine - tabletti, kalvopäällysteinen - 5 mg / 1,25 mg - perindopriili ja diureetit

Suomi - suomi - Fimea (Suomen lääkevirasto)

les laboratoires servier - indapamide, perindopril arginine - tabletti, kalvopäällysteinen - 10 mg / 2,5 mg - perindopriili ja diureetit

Euroopan unioni - suomi - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - kystinen fibroosi - muut hengitysteiden tuotteet - orkambi-tabletit on tarkoitettu kystisen fibroosin (cf) potilailla, jotka ovat iältään 6 vuotta ja vanhemmat, jotka ovat homotsygoottisia f508del-mutaation cftr geeni. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Euroopan unioni - suomi - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - kystinen fibroosi - muut hengitysteiden tuotteet - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Euroopan unioni - suomi - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - kystinen fibroosi - muut hengitysteiden tuotteet - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.